Data Standards for Tobacco Research and Scientific Review Phase 2
ID: 347925Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Eligible Applicants

Small Businesses

Funding Category

Consumer Protection

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347925
Timeline
    Description

    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Data Standards for Tobacco Research and Scientific Review Phase 2," aimed at enhancing tobacco research and public health outcomes. The initiative seeks applications from small businesses to develop open, consensus-based data standards and terminologies that facilitate scientific review and evaluation in tobacco studies. This effort is crucial for promoting standardized data usage among federal regulators, the tobacco industry, and global organizations, ultimately improving data sharing and analysis. The estimated total program funding is $400,000, with two awards expected, and interested applicants can reach out to Rene A Vasquez at rene.vasquez@fda.hhs.gov or by phone at 301-796-3546. The synopsis is anticipated to be posted on October 1, 2023, with a closing date of December 1, 2023, and project start date projected for May 1, 2024.

    Point(s) of Contact
    Rene A Vasquez Grants Management Specialist
    (301) 796-3546
    rene.vasquez@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing the upcoming Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional), aimed at supporting high-priority research topics in tobacco regulatory science. This program seeks to fund innovative research that will provide scientific data to inform the FDA's regulatory authorities concerning tobacco products, particularly in relation to the Family Smoking Prevention and Tobacco Control Act (FSPTCA). With an estimated total funding of $500,000 and the expectation of awarding four grants, the Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2025, with applications due in Winter 2026. For further inquiries, interested applicants can contact Erik Rodriquez, Ph.D., at TRSP@nih.gov or by phone at 301-827-2830.
    High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)" aimed at supporting research that informs the FDA's tobacco regulatory authorities. This initiative seeks applications for high-priority research projects that address topics such as addiction, behavior, health effects, product composition, and toxicity, with the goal of enhancing the scientific data available for tobacco product regulation. The total estimated funding for this program is $7 million, with an award ceiling of $500,000 and an expected eight awards to be made. Interested applicants can reach out to Erik Rodriquez, Ph.D., M.P.H., at TRSP@nih.gov or by phone at 301-827-2830, with applications due by May 4, 2026, and awards expected to be announced by December 4, 2026.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science, inviting R01 research applications that focus on biomedical and behavioral research to inform tobacco product regulation. This initiative aims to generate scientific data that will enhance public health protections related to tobacco use, with a particular emphasis on fostering diverse perspectives through a simplified peer review framework. The total estimated funding for this program is $4 million, with an award ceiling of $500,000 for each of the anticipated five awards, and the NOFO is expected to be published in Winter 2024, with applications due in Summer 2025. Interested applicants should prepare to submit new applications, as only new proposals will be considered, and further details will be available upon the official release of the NOFO.
    Collaborations to Enhance Drug Development and Regulatory Science
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for a federal grant titled "Collaborations to Enhance Drug Development and Regulatory Science." This opportunity aims to establish cooperative agreements that support Public-Private Partnerships and collaborative activities under the Critical Path Initiative, focusing on innovative projects that enhance drug product development, advanced manufacturing, and the translation of scientific discoveries into therapeutics. The initiative is crucial for fostering innovation in drug safety, efficacy, quality, and performance, with a total funding ceiling of $5 million available for six expected awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call (240) 402-7610 for further information.
    Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional) to support early-stage researchers in tobacco regulatory science. This funding opportunity aims to facilitate small-scale projects that generate data to inform the U.S. Food and Drug Administration's (FDA) regulations on tobacco products, in alignment with the Family Smoking Prevention and Tobacco Control Act (FSPTCA). Eligible applicants include various organizations such as higher education institutions, non-profits, and government entities, with awards of up to $75,000 available for projects lasting up to two years, and a total funding pool of $500,000 anticipated for fiscal year 2026. Interested applicants should submit their proposals through Grants.gov and eRA Commons by the closing date of July 14, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is announcing a funding opportunity for a Cooperative Agreement titled "Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)." This initiative aims to support research and development of practices that mitigate risks associated with nitrosamine impurities in human drugs, thereby enhancing public health safety while ensuring access to essential therapeutic drugs. The FDA seeks to fund one award with a total funding amount of $350,000, with no cost-sharing or matching requirements. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information. The opportunity is forecasted for fiscal year 2024, and applicants may submit multiple distinct applications, adhering to guidelines regarding overlapping submissions.
    Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines." This initiative aims to support the dissemination of clinical practice guidelines, particularly those developed with prior FDA cooperative agreements, by requiring applicants to propose a comprehensive plan for developing, evaluating, and distributing materials that facilitate this dissemination, with a strong emphasis on equity. The funding for this opportunity has an award ceiling and floor of $1,000,000, with one award expected to be made in fiscal year 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further details.
    Manufactured Foods Flexible Funding Model (MF-FFM)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Manufactured Foods Flexible Funding Model (MF-FFM)" aimed at advancing a nationally integrated food safety system. This cooperative agreement seeks to support initiatives related to Manufactured Food Regulatory Program Standards (MFRPS), dietary supplement safety, and state compliance and enforcement infrastructure, with a focus on enhancing food safety practices across jurisdictions. The program is critical for ensuring that state regulatory programs maintain high-quality standards and best practices in food safety. Interested applicants, which include state, local, territorial, and tribal agencies, as well as non-profit training entities collaborating with higher education institutions, can reach out to Gordana Zuber at gordana.zuber@fda.hhs.gov or by phone at 301-348-1747 for further details. The estimated project start date is July 1, 2023, with approximately 50 awards expected under this discretionary funding opportunity.
    Novel approaches to support therapeutic development in ultra-rare cancers
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel approaches to support therapeutic development in ultra-rare cancers," aimed at exploring innovative methods to enhance therapeutic development for these specific cancer types. This initiative is particularly focused on small businesses, which are encouraged to apply for this cooperative agreement that falls under the discretionary category of funding. The program is significant as it addresses the critical need for advancements in treatment options for ultra-rare cancers, which often lack sufficient research and development support. Interested applicants can reach out to Patrick Johnson, Grants Management Specialist, at patrick.johnson@fda.hhs.gov or call 301-796-0154 for further information. The expected number of awards is two, with no cost-sharing requirement, and the opportunity is set for the fiscal year 2026.
    Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives." This cooperative agreement aims to enhance the capabilities of State animal food regulatory programs to fully implement the Animal Feed Regulatory Program Standards (AFRPS) and to develop standardized processes that promote mutual reliance between federal and state regulatory efforts. The initiative is crucial for establishing a nationally integrated animal food safety system, ensuring that state programs can effectively manage animal food safety regulations. Interested organizations must meet specific eligibility criteria, including the ability to enter into a 20.88 information disclosure agreement with the FDA, and the funding amount is set at $10.6 million, with approximately 30 awards expected. For further inquiries, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610.